NCT04876248View on ClinicalTrials.gov

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 19, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions
Plasma Cell Myeloma
Interventions
BIOLOGICAL

Belantamab Mafodotin

Given IV

DRUG

Lenalidomide

Given PO

Trial Locations (1)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT04876248 - Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant | Biotech Hunter | Biotech Hunter